Admin Portal
Data Dashboard
INHALEarning
Ask the Pharmacist
Contact Us

Evolving Best Practice: Individualizing Therapy in Severe Asthma – CME Activity

Dr. Njira Lugogo discusses the use of biologic agents in severe asthma, reviewing the approach to management, biomarker use, and specific inflammatory cascade targets. A discussion of real-world trial data in addition to extension study data underscores the effectiveness of biologic agents in reducing exacerbation, which raises the questions for some patients, is asthma remission possible, and what does it look like? Earn 1.00 CME/CE Credit.

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Discuss the relationship between pathophysiology, phenotypes/endotypes, and biological agent treatment targets in asthma
  • Review emerging data, including real-world and long-term extension studies, on biologic treatments for patients with severe asthma
  • Individualize biologic therapy selection for patients with severe asthma based on phenotype, comorbidities, and patient preferences
View the activity here

Subscribe to Our Newsletter

INHALE prepares regular PO and Clinical level newsletters that contain:

  • coordinating center updates
  • upcoming important events
  • tips and tricks for utilizing our website and portals
  • relevant articles and resources
  • and the latest asthma and COPD research
Twitter Instagram Youtube Linkedin


Arbor Lakes Building 3, Floor 3
4251 Plymouth Rd.
Ann Arbor, MI 48105

Support for the INHALE CQI is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program. BCBSM’s Value Partnerships program provides clinical and executive support for all CQI programs. 

Although Blue Cross Blue Shield of Michigan and the INHALE CQI work in partnership, the opinions, beliefs, and viewpoints expressed by INHALE CQI do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.